Lilly said in April that Takeda would take over U.S. marketing for type 2 diabetes treatment Actos. The firm completed Actos detailing obligations in the U.S. at the end of Q1 but will continue to receive royalties on sales through the end of September, after which it will begin receiving a declining residual royalty. In a July 31 story, "The Pink Sheet" stated the Takeda agreement expired in April (1"The Pink Sheet" July 31, 2006, p. 4). Looking forward Lilly expects SG&A to grow at a lower rate than sales. The story reported the firm expected SG&A to grow at a higher rate than sales...
You may also be interested in...
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
Four US senators are leading a bipartisan effort to bring potentially life-saving medical treatments to Medicare beneficiaries by requiring reimbursement for breakthrough technologies cleared by the FDA.
A joint final order from the US Department of Health and Human Services and the Food and Drug Administration says makers of the low-risk gloves must have 510(k) clearance before sending their products to market.